McKesson CorporationOpportunity Rank #105(MCK) Intrinsic Value & DCF Analysis (2026)
Current Price
$824.49
Last updated: Jul 24, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
As of 2026-07-24
Still researching stocks one at a time?
Intrinziq helps you:
- Turn your stock-picking rules into repeatable strategies
- Find better setups across hundreds of stocks automatically
- Backtest your strategy before putting money to work
The intrinsic value of McKesson Corporation (MCK) is estimated at $943.58 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $824.49, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 4.36% long-term growth rate and an 8.50% discount rate (calculated: 7.38%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of McKesson Corporation (MCK) is estimated at $943.58 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $824.49, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 4.36% long-term growth rate and an 8.50% discount rate (calculated: 7.38%), reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning a higher return on invested capital than it costs to raise that capital — a sign of strong, efficient value creation.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Monitor whether valuation discount remains above 10%.
- Confirm ROIC stays above cost of capital over coming quarters.
- Follow narrative trend for meaningful shifts in the score direction.
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates McKesson Corporation's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
McKesson CorporationHealthcare
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.